Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > BUSINESS
BUSINESS
- Mitsubishi Tanabe Looks to Double Late-Stage Pipelines; Faster Decisions Hold Key in Curbing Costs
October 3, 2016
- Data Out to Support Long-Term Use of Entyvio: Takeda
October 3, 2016
- Eisai to Kick Off Global PIII for Lenvatinib as First-Line RCC Therapy
October 3, 2016
- Mochida to Solely Distribute Janssen’s Pain Drug Tramcet from January
October 3, 2016
- Teva Pharma Japan Renamed “Teva Takeda Pharma”
October 3, 2016
- Takecab Most Heavily Promoted Drug in August: Anterio
October 3, 2016
- Suzuken’s Harvoni Sales Sag 70% from Peak, Wholesaler Earnings Certain to Take Hit
September 30, 2016
- Daiichi Sankyo, Zymeworks Seal Immuno-Oncology Cross-Licensing Pact
September 30, 2016
- Chugai Licenses Atopic Dermatitis Hopeful to Maruho in Japan, Retains Rights for Hemodialysis Pruritus
September 29, 2016
- Maruho Gets Rights to Astellas’ JAK Inhibitor for Skin Diseases
September 29, 2016
- Pruritus Drug Remitch Filed for Use in Peritoneal Dialysis Patients
September 29, 2016
- Tokyo Startup’s Osteoarthritis Drug Hopeful on Tap for PIb Launch by Year-End
September 28, 2016
- Celgene Poised to Boost Japan Organization as New Launch Nears
September 28, 2016
- Psoriasis Drug Lumicef to Hit Shelves on Sept. 30: Kyowa Kirin
September 28, 2016
- Sawai Files Myrbetriq Generic in US, Its 2nd Product after Livalo Copy
September 28, 2016
- Eisai Seeks Label Expansion for Fycompa to Include Monotherapy
September 28, 2016
- Novel MR Antagonist Enters Japan PIII for Hypertension: Daiichi Sankyo
September 28, 2016
- Otsuka-Lundbeck’s Alzheimer’s Med Idalopirdine Stumbles in PIII
September 27, 2016
- Rexulti OK’ed for Schizophrenia Maintenance Therapy in US
September 27, 2016
- Daiichi Sankyo Seeks RA Indication for Pralia
September 26, 2016
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…